Yang, Y., Qu, S., Li, J., Hu, C., Xu, M., Li, W., Zhou, T., Shen, L., Wu, H., Lang, J., Hu, G., Luo, Z., Fu, Z., Qu, S., Feng, W., Chen, X., Lin, S., Zhang, W., Li, X., Sun, Y., Lin, Z., Lin, Q., Lei, F., Long, J., Hong, J., Huang, X., Zeng, L., Wang, P., He, X., Zhang, B., Yang, Q., Zhang, X., Zou, J., Fang, W., & Zhang, L. (2021). camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet oncology, 22(8), 1162–1174. http://access.bl.uk/ark:/81055/vdc_100136720507.0x00001b